Genomictree Inc. Cash Flow-to-Debt Ratio
Genomictree Inc. cash flow-to-debt ratio. Genomictree Inc. (228760) has a Cash Flow-to-Debt Ratio of -0.59x as of December 2025, meaning its operating cash flow of ₩-3.21 Billion could theoretically repay -1% of its total liabilities (₩5.45 Billion) in one year. See Genomictree Inc. leverage flexibility ratio to measure the company's free cash flow as a share of total liabilities.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cash Flow-to-Debt Ratio of Genomictree Inc. (2020–2025)
Cash flow-to-debt ratio of Genomictree Inc. from 2020 to 2025. Historical debt coverage capacity for Genomictree Inc. across 6 annual periods. Check 228760 total capital reinvestment ratio to assess the company's total reinvestment commitment from operating cash flow.
Genomictree Inc. Cash Flow-to-Debt Ratio by Year (2020–2025)
Genomictree Inc. cash flow-to-debt ratio by year from 2020 to 2025. Year-by-year debt coverage analysis for Genomictree Inc.. For the full cash flow conversion analysis, see how efficiently does Genomictree Inc. generate cash.
| Year | CF-to-Debt Ratio | Operating CF (KRW) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -1.87x | ₩-10.19 Billion | ₩5.45 Billion | ▲ +12.8% |
| 2024 | -2.15x | ₩-13.63 Billion | ₩6.36 Billion | ▼ -54.0% |
| 2023 | -1.39x | ₩-10.88 Billion | ₩7.81 Billion | ▼ -1915.2% |
| 2022 | 0.08x | ₩4.29 Billion | ₩55.86 Billion | ▲ +162.4% |
| 2021 | -0.12x | ₩-7.63 Billion | ₩62.05 Billion | ▲ +72.7% |
| 2020 | -0.45x | ₩-10.19 Billion | ₩22.64 Billion | — |